Navelbine (Vinorelbine Tartrate)

Vinorelbine tartrate binds to tubulin, inhibiting microtubule assembly. This blocks the formation of the mitotic spindle, arresting cells in the M phase of the cell cycle and ultimately leading to apoptosis of cancer cells that rely on microtubule dynamics for division.

The prescribed dose of Navelbine is determined by the treating oncologist based on the patient’s clinical condition, body surface area, and treatment protocol. Dosage adjustments may be required for hepatic function, blood‑count levels, or concomitant therapies.

The safety of vinorelbine tartrate in pregnancy and lactation has not been established. It is generally advised to avoid use in pregnant or nursing women unless the potential benefit justifies the potential risk to the fetus or infant.

To order Navelbine, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Vinorelbine belongs to the Vinca alkaloid class, which differs from taxane‑based agents by targeting tubulin assembly at a distinct binding site. Compared with other Vinca alkaloids, vinorelbine has a more favourable toxicity profile for certain patients, but choice of therapy depends on tumour type, prior treatment and individual tolerance.

Navelbine capsules should be stored at temperatures below 25 °C, in the original container, protected from moisture and direct sunlight. Keep the product out of reach of children and avoid exposure to excessive heat or humidity.

Navelbine is taken orally as a capsule. The capsule should be swallowed whole with water, preferably on an empty stomach or as directed by the prescribing physician. Administration timing may be coordinated with other chemotherapy agents in a treatment cycle.

The most serious risks include severe neutropenia with fever, which can lead to life‑threatening infections, pulmonary toxicity presenting as cough or dyspnoea, and rare allergic reactions such as anaphylaxis. Patients should be monitored closely for signs of infection, respiratory changes, or hypersensitivity.

Navelbine should not be used in patients with known hypersensitivity to vinorelbine or other Vinca alkaloids, in those with severe bone‑marrow suppression, uncontrolled infections, or significant hepatic impairment without dose adjustment. It is also contraindicated during pregnancy unless the benefits outweigh the risks.